Akademik Veri Yönetim Sistemi
27. ULUSAL ELEKTRON MİKROSKOPİ KONGRESİ - EMK 2025, İstanbul, Türkiye, 25 - 27 Eylül 2025, cilt.1, sa.1, ss.104-105, (Tam Metin Bildiri)
INTRODUCTION: Psoriasis is a multifactorial, chronic inflammatory skin disease characterized by epidermal hyperproliferation, keratinocyte differentiation abnormalities, and immune system dysfunction. The NLRP3 inflammasome complex has emerged as a key regulatory element in the pathogenesis of the disease. Current treatment options are often limited by reduced long-term efficacy and undesirable side effects, underscoring the need for novel molecular targets. OBJECTIVE: This study sought to assess the therapeutic efficacy of Loganin (LOG), a natural iridoid glycoside, in an imiquimod (IMQ)-induced psoriasis mouse model. MATERIALS& METHODS: Thirty-five BALB/c mice were randomly assigned to five groups: control, saline+vaseline (SAL+VAS), LOG, IMQ, and IMQ+LOG. Psoriatic inflammation was elicited by daily topical administration of IMQ for seven consecutive days. The severity of the disease was evaluated utilizing the Psoriasis Area and Severity Index (PASI). Histopathological and morphometric changes were examined through H&E and Masson’s trichrome staining, alongside volumetric assessment using the Cavalieri method. mRNA expression levels of NLRP3, ASC, caspase-1, IL-1β, gasdermin, TNF-α, and IL-17A were quantified via qPCR, and serum cytokine levels of IL-1β and IL-17A were measured using ELISA. NLRP3, ASC, caspase-1, and IL-1β expressions were assessed by immunohistochemistry. Furthermore, immunofluorescence staining for PCNA, CK-17, and VEGFR2 was measured utilizing ImageJ. RESULTS: LOG treatment significantly improved epidermal thickness, lymphocytic infiltration, collagen density, and vascularization. Immunohistochemical findings demonstrated a significant reduction in the expression of NLRP3, ASC, caspase-1, and IL-1β proteins. Consistently, qPCR results demonstrated downregulation of inflammasome-related genes and proinflammatory cytokines. Furthermore, immunofluorescence intensities of PCNA, CK-17, and VEGFR2 were significantly reduced. LOG also decreased serum levels of IL-1β and IL-17A, signifying a reduction in the systemic inflammation. CONCLUSION: The results revealed that LOG exhibits considerable anti-inflammatory effects via inhibiting NLRP3 inflammasome activation and associated inflammatory pathways. LOG may serve as a new candidate for future antipsoriatic therapeutics focused on inflammasome-mediated cutaneous inflammation. Keywords: Imiquimod, Psoriasis, Loganin, Inflammation, NLRP3 inflammasome